Our MD & CEO Leslie Chong joins the Money News radio program which airs on 2GB (Sydney), 3AW (Melbourne) and 4BC (Brisbane). $IMU A fantastic interview - listen at: podcasts.apple.com/au/podcast/les…

Heres another great podcast for anyone following the Imugene | Cancer Immunotherapies story : after-market.simplecast.com/episodes/imuge…

Bright Minds: Parker Institute for Cancer Immunotherapy's John Connolly gives a breakdown of what he is seeing at #SITC23. Full video: biotechtv.com/post/parker-in…

Imugene Investor Webinar: MAST Study Update Today at 11:00am AEDT Register at us02web.zoom.us/webinar/regist… The webinar will discuss the clinical trial update of Phase 1 MAST trial evaluating the safety and efficacy of novel cancer-killing virus CF33-hNIS (VAXINIA).

Really worth a look at this webinar from Imugene | Cancer Immunotherapies for an update on progress I’m the vaxinia trial. A hopeful new treatment for #MBC

Huge Congratulations to Imugene | Cancer Immunotherapies and Yuman Fong receiving Fast Track Designation this morning for the CF33 Vaxinia trial in treating Bile Duct cancer. Hoping for similar outstanding results in #MBC investorhub.imugene.com/announcements/…

Our Cureteq AG team has closed its successful in-licensing deal for the first-in-class compound TEQ103. Read more about it here: cureteq.com/2023/11/oncote… #pharmanews #health #drugassets #healthcare #patients #oncology #CancerResearch

Watch a killer T cell of the immune system destroying a monstrous ovarian cancer cell. [📹 Alex Ritter] x.com/RKian_Service/…

Happy new year from Australia my X friends. Here’s to a happy and healthy 2024

Congrats to Strand Therapeutics!

Imugene was on the Seven Network last night showcasing the potential of our #CF33 #oncolytic virus to target and fight various #cancers and #tumour types. A big thank you to the patients involved, Professor Yuman Fong for his scientific leadership, and Amber Laidler for

The first patient, with bile tract cancer, has been dosed in the intravenous monotherapy arm of the #OASIS trial of our #virotherapy drug candidate #onCARlytics (on-CAR-19, CF33-CD19 HOV4). The trial is a world-first in combining a CD19-expressing oncolytic virus with a #CD19

Our CEO and Managing Director, Leslie Chong, joins Proactive Australia to discuss our most recent milestone; the first patient with bile tract cancer being dosed in the intravenous monotherapy arm of the OASIS trial of our virotherapy drug candidate onCARlytics (on-CAR-19, CF33-CD19

Congratulations Imugene | Cancer Immunotherapies a hopeful new treatment option for #MBC. Wishing you every success

We've requested a Type C meeting with the FDA to align on the design and objectives of a registration-enabling trial for #pelareorep in HR+/HER2- metastatic breast cancer, additional details in the PR: oncolyticsbiotech.com/press_releases… #BreastCancer #BreastCancerResearch #biotech #cancer

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors. Pleasure expedite for Er+Her2- metastatic breast cancer. $RNAZ #MBC #bcsm pipelinereview.com/transcode-ther…

This immune cell soldier (yellow) fights a highly aggressive cancer cell (magenta). x.com/AzzaGadir/stat… The cancer cell is a tough opponent to face and it takes multiple punches to knock it out. The cancer cell contains a sensor that lights up when it is being punched by a

A timeline cleanse with the Southern Lights

Some great progress from TransCode Therapeutics Zdravka Medarova congratulations and here’s hoping for more positive news ir.transcodetherapeutics.com/news-releases/…

The (other) C Word I wish they would spend the money on research instead of awareness. We are aware!!! Some breast cancer foundations spend 5% on research but have a tagline, “Help is find a cure.” They cure Stage IV, they cure everyone. Duh!